Floatz logo

Anamorelin

Cachexia

Helsinn Therapeutics (U.S.), IncSmall moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Cachexia cohort.

Asset / SponsorPhaseRating
Ponsegromab
Pfizer
Phase 2/3BB
MEGESTROL ACETATE IMPURITY B
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3BB
Infliximab
Centocor, Inc.
Phase 3BB
Nanocrystalline Megestrol Acetate Suspension
Nanfang Hospital, Southern Medical University
Phase 3BB
Docetaxel
Alliance for Clinical Trials in Oncology
Phase 3B

View all 29 →

Same molecule, other indications

Anamorelin is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
cancerDormant
BB
Indicative ·
68 / 100
View asset →
AnorexiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →